Arterial and venous dilation by nitroprusside and nitroglycerin--is there a difference?

Area of Science:

• Cardiovascular Pharmacology
• Anesthesiology
• Vascular Physiology

Background:

• Nitroprusside and nitroglycerin are commonly used vasodilators in cardiac surgery.
• Understanding their differential effects on arterial and venous systems is crucial for hemodynamic management.
• Previous studies have yielded mixed results regarding their comparative efficacy.

Purpose of the Study:

• To compare the whole-body arterial and venous dilating properties of nitroprusside and nitroglycerin.
• To assess the influence of different infusion rates on their vasodilatory effects.
• To correlate systemic effects with forearm vascular measurements.

Main Methods:

• A randomized study involving 20 adult patients undergoing cardiopulmonary bypass.
• Administration of nitroprusside and nitroglycerin at varying doses (1.0, 1.5, 2.0 microgram/kg/min).
• Simultaneous measurement of whole-body arterial and venous tone, alongside forearm plethysmography.

Main Results:

• Nitroprusside demonstrated superior whole-body arterial vasodilation at 1.5 and 2.0 microgram/kg/min.
• Nitroglycerin proved more effective as a whole-body venous vasodilator at the same higher doses.
• No significant difference in overall vasodilation was observed at 1.0 microgram/kg/min; forearm measurements did not differentiate drug effects.

Conclusions:

• Nitroprusside and nitroglycerin exhibit distinct dose-dependent, whole-body vasodilatory profiles during cardiopulmonary bypass.
• Clinical selection should consider the desired effect on arterial versus venous capacitance.
• Forearm vascular studies may not accurately reflect systemic drug responses in this setting.